Moreover, although the tumor burden was substantially increased in the IL-33-expressing glioma compared to the IL-33-negative tumors, the actual size of the tumor suggests that the clinical criteria for endpoint were not reached exclusively due to tumor burden. This evidence concerns the gene IL33 and glioma.